NKG2D initiates caspase-mediated CD3ζ degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease

Journal of Immunology

Volumn 185, Issue 10, 2010, Pages 5732-5742

  Hanaoka, Nobuyoshi ^a,b   Jabri, Bana ^c   Dai, Zhenpeng ^a   Ciszewski, Cezary ^c   Stevens, Anne M ^d   Yee, Cassian ^a   Nakakuma, Hideki ^b   Spies, Thomas ^a   Groh, Veronika ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF CHICAGO   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 3; CASPASE 7; CD3 ANTIGEN; CD3 ZETA ANTIGEN; FAS ANTIGEN; FAS LIGAND; FC RECEPTOR; LIGAND; LYMPHOCYTE RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; AUTOIMMUNE DISEASE; BLOOD; CELL STIMULATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; EX VIVO STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; JUVENILE; MEDIATOR; NATURAL KILLER CELL; ONSET AGE; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD3; AUTOIMMUNE DISEASES; CASPASES; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 78650642570     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002092     Document Type: Article

References (78)

1. Burgess, S. J., K. Maasho, M. Masilamani, S. Narayanan, F. Borrego, and J. E. Coligan. 2008. The NKG2D receptor: immunobiology and clinical implications. Immunol. Res. 40:18-34.
2. Bauer, S., V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T. Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-729.
3. Wu, J., Y. Song, A. B. Bakker, S. Bauer, T. Spies, L. L. Lanier, and J. H. Phillips. 1999. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730-732.
4. Groh, V., R. Rhinehart, J. Randolph-Habecker, M. S. Topp, S. R. Riddell, and T. Spies. 2001. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2:255-260.
5. Meresse, B., Z. Chen, C. Ciszewski, M. Tretiakova, G. Bhagat, T. N. Krausz, D. H. Raulet, L. L. Lanier, V. Groh, T. Spies, et al. 2004. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21:357-366.
6. Ehrlich, L. I., K. Ogasawara, J. A. Hamerman, R. Takaki, A. Zingoni, J. P. Allison, and L. L. Lanier. 2005. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J. Immunol. 174:1922-1931.
7. Bryceson, Y. T., M. E. March, H. G. Ljunggren, and E. O. Long. 2006. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107:159-166.
8. Venkataraman, G. M., D. Suciu, V. Groh, J. M. Boss, and T. Spies. 2007. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J. Immunol. 178:961-969.
9. Groh, V., S. Bahram, S. Bauer, A. Herman, M. Beauchamp, and T. Spies. 1996. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93:12445-12450.
10. Groh, V., R. Rhinehart, H. Secrist, S. Bauer, K. H. Grabstein, and T. Spies. 1999. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 96:6879-6884.
11. Groh, V., A. Bruhl, H. El-Gabalawy, J. L. Nelson, and T. Spies. 2003. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 100:9452-9457.
12. Hüe, S., J. J. Mention, R. C. Monteiro, S. Zhang, C. Cellier, J. Schmitz, V. Verkarre, N. Fodil, S. Bahram, N. Cerf-Bensussan, and S. Caillat-Zucman. 2004. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21:367-377.
13. Stern-Ginossar, N., and O. Mandelboim. 2009. An integrated view of the regulation of NKG2D ligands. Immunology 128:1-6.
14. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738.
15. Doubrovina, E. S., M. M. Doubrovin, E. Vider, R. B. Sisson, R. J. O'Reilly, B. Dupont, and Y. M. Vyas. 2003. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 171:6891-6899.
16. Mincheva-Nilsson, L., O. Nagaeva, T. Chen, U. Stendahl, J. Antsiferova, I. Mogren, J. Hernestål, and V. Baranov. 2006. Placenta-derived soluble MHC class I chain-related molecules down-regulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival. J. Immunol. 176:3585-3592.
17. Roda-Navarro, P., and H. T. Reyburn. 2009. The traffic of the NKG2D/Dap10 receptor complex during natural killer (NK) cell activation. J. Biol. Chem. 284:16463-16472.
18. Salih, H. R., H. G. Rammensee, and A. Steinle. 2002. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169:4098-4102.
19. Salih, H. R., S. Holdenrieder, and A. Steinle. 2008. Soluble NKG2D ligands: prevalence, release, and functional impact. Front. Biosci. 13:3448-3456.
20. Coudert, J. D., L. Scarpellino, F. Gros, E. Vivier, and W. Held. 2008. Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood 111:3571-3578.
21. Coudert, J. D., J. Zimmer, E. Tomasello, M. Cebecauer, M. Colonna, E. Vivier, and W. Held. 2005. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 106:1711-1717.
22. Moretta, A., C. Bottino, M. Vitale, D. Pende, C. Cantoni, M. C. Mingari, R. Biassoni, and L. Moretta. 2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19:197-223.
23. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9:495-502.
24. Weissman, A. M., M. Baniyash, D. Hou, L. E. Samelson, W. H. Burgess, and R. D. Klausner. 1988. Molecular cloning of the zeta chain of the T cell antigen receptor. Science 239:1018-1021.
25. Weiss, A. 1993. T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein-tyrosine kinases. Cell 73:209-212.
26. Samelson, L. E. 2002. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu. Rev. Immunol. 20:371-394.
27. Myers, M. D., L. L. Dragone, and A. Weiss. 2005. Src-like adaptor protein down-regulates T cell receptor (TCR)-CD3 expression by targeting TCRzeta for degradation. J. Cell Biol. 170:285-294.
28. Taylor, D. D., S. A. Sullivan, A. C. Eblen, and C. Gercel-Taylor. 2002. Modulation of T-cell CD3-zeta chain expression during normal pregnancy. J. Reprod. Immunol. 54:15-31.
29. Baniyash, M. 2004. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat. Rev. Immunol. 4:675-687.
30. Dai, Z., C. J. Turtle, G. C. Booth, S. R. Riddell, T. A. Gooley, A. M. Stevens, T. Spies, and V. Groh. 2009. Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J. Exp. Med. 206:793-805.
31. Jabri, B., J. M. Selby, H. Negulescu, L. Lee, A. I. Roberts, A. Beavis, M. Lopez-Botet, E. C. Ebert, and R. J. Winchester. 2002. TCR specificity dictates CD94/NKG2A expression by human CTL. Immunity 17:487-499.
32. Li, Y., M. Bleakley, and C. Yee. 2005. IL-21 influences the frequency, pheno-type, and affinity of the antigen-specific CD8 T cell response. J. Immunol. 175:2261-2269.
33. Steinle, A., P. Li, D. L. Morris, V. Groh, L. L. Lanier, R. K. Strong, and T. Spies. 2001. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 53:279-287.
34. Wu, J., V. Groh, and T. Spies. 2002. T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial gamma delta T cells. J. Immunol. 169:1236-1240.
35. Groh, V., A. Steinle, S. Bauer, and T. Spies. 1998. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 279:1737-1740.
36. Groh, V., K. Smythe, Z. Dai, and T. Spies. 2006. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat. Immunol. 7:755-762.
37. Tang, F., Z. Chen, C. Ciszewski, M. Setty, J. Solus, M. Tretiakova, E. Ebert, J. Han, A. Lin, S. Guandalini, et al. 2009. Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15. J. Exp. Med. 206:707-719.
38. Valitutti, S., S. Müller, M. Salio, and A. Lanzavecchia. 1997. Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. J. Exp. Med. 185:1859-1864.
39. Verneris, M. R., M. Karami, J. Baker, A. Jayaswal, and R. S. Negrin. 2004. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103:3065-3072.
40. Eagle, R. A., and J. Trowsdale. 2007. Promiscuity and the single receptor: NKG2D. Nat. Rev. Immunol. 7:737-744.
41. Eagle, R. A., J. A. Traherne, J. R. Hair, I. Jafferji, and J. Trowsdale. 2009. ULBP6/RAET1L is an additional human NKG2D ligand. Eur. J. Immunol. 39:3207-3216.
42. Weiss, A., and D. R. Littman. 1994. Signal transduction by lymphocyte antigen receptors. Cell 76:263-274.
43. Meresse, B., S. A. Curran, C. Ciszewski, G. Orbelyan, M. Setty, G. Bhagat, L. Lee, M. Tretiakova, C. Semrad, E. Kistner, et al. 2006. Reprogramming of CTLs into natural killer-like cells in celiac disease. J. Exp. Med. 203:1343-1355.
44. Tang, Q., B. Grzywacz, H. Wang, N. Kataria, Q. Cao, J. E. Wagner, B. R. Blazar, J. S. Miller, and M. R. Verneris. 2008. Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional. J. Immunol. 181:4507-4515.
45. Brando, C., S. Mukhopadhyay, E. Kovacs, R. Medina, P. Patel, T. L. Catina, K. S. Campbell, and D. Santoli. 2005. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104. J. Leukoc. Biol. 78:359-371.
46. Cooper, M. A., T. A. Fehniger, and M. A. Caligiuri. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22:633-640.
47. Nakajima, H., and M. Colonna. 2000. 2B4: an NK cell activating receptor with unique specificity and signal transduction mechanism. Hum. Immunol. 61:39-43.
48. Jang, I. K., and H. Gu. 2003. Negative regulation of TCR signaling and T-cell activation by selective protein degradation. Curr. Opin. Immunol. 15:315-320.
49. Correa, M. R., A. C. Ochoa, P. Ghosh, H. Mizoguchi, L. Harvey, and D. L. Longo. 1997. Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J. Immunol. 158:5292-5296.
50. Brundula, V., L. J. Rivas, A. M. Blasini, M. París, S. Salazar, I. L. Stekman, and M. A. Rodríguez. 1999. Diminished levels of T cell receptor zeta chains in peripheral blood T lymphocytes from patients with systemic lupus eryth-ematosus. Arthritis Rheum. 42:1908-1916.
51. Takahashi, A., K. Kono, H. Amemiya, H. Iizuka, H. Fujii, and Y. Matsumoto. 2001. Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apoptosis and down-regulation of TCR zeta molecules in patients with gastric cancer. Clin. Cancer Res. 7:74-80.
52. Wieckowski, E., G. Q. Wang, B. R. Gastman, L. A. Goldstein, and H. Rabinowich. 2002. Granzyme B-mediated degradation of T-cell receptor zeta chain. Cancer Res. 62:4884-4889.
53. Torelli, G. F., R. Paolini, C. Tatarelli, A. Soriani, A. Vitale, A. Guarini, A. Santoni, and R. Foa. 2003. Defective expression of the T-cell receptor-CD3 zeta chain in T-cell acute lymphoblastic leukaemia. Br. J. Haematol. 120:201-208.
54. Tsuzaka, K., I. Fukuhara, Y. Setoyama, K. Yoshimoto, K. Suzuki, T. Abe, and T. Takeuchi. 2003. TCR zeta mRNA with an alternatively spliced 3'-untranslated region detected in systemic lupus erythematosus patients leads to the down-regulation of TCR zeta and TCR/CD3 complex. J. Immunol. 171:2496-2503.
55. Krishnan, S., J. G. Kiang, C. U. Fisher, M. P. Nambiar, H. T. Nguyen, V. C. Kyttaris, B. Chowdhury, V. Rus, and G. C. Tsokos. 2005. Increased caspase-3 expression and activity contribute to reduced CD3zeta expression in systemic lupus erythematosus T cells. J. Immunol. 175:3417-3423.
56. Crispín, J. C., V. C. Kyttaris, Y. T. Juang, and G. C. Tsokos. 2008. How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends Immunol. 29:110-115.
57. Vaknin, I., L. Blinder, L. Wang, R. Gazit, E. Shapira, O. Genina, M. Pines, E. Pikarsky, and M. Baniyash. 2008. A common pathway mediated through Tolllike receptors leads to T-and natural killer-cell immunosuppression. Blood 111:1437-1447.
58. Díaz-Benítez, C. E., K. R. Navarro-Fuentes, J. A. Flores-Sosa, J. Juárez-Díaz, F. J. Uribe-Salas, E. Román-Basaure, L. E. González-Mena, P. Alonso de Ruíz, G. López-Estrada, A. Lagunas-Martínez, et al. 2009. CD3zeta expression and T cell proliferation are inhibited by TGF-beta1 and IL-10 in cervical cancer patients. J. Clin. Immunol. 29:532-544.
59. Caplan, S., and M. Baniyash. 2000. Searching for significance in TCR-cytoskeleton interactions. Immunol. Today 21:223-228.
60. Nambiar, M. P., S. Krishnan, V. G. Warke, and G. C. Tsokos. 2004. TCR zeta-chain abnormalities in human systemic lupus erythematosus. Methods Mol. Med. 102:49-72.
61. Takeuchi, T., K. Tsuzaka, M. Pang, K. Amano, J. Koide, and T. Abe. 1998. TCR zeta chain lacking exon 7 in two patients with systemic lupus erythematosus. Int. Immunol. 10:911-921.
62. Gastman, B. R., D. E. Johnson, T. L. Whiteside, and H. Rabinowich. 1999. Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer Res. 59:1422-1427.
63. Menné, C., J. P. Lauritsen, J. Dietrich, J. Kastrup, A. K. Wegener, P. S. Andersen, N. Odum, and C. Geisler. 2001. T-cell receptor downregulation by ceramide-induced caspase activation and cleavage of the zeta chain. Scand. J. Immunol. 53:176-183.
64. Fischer, U., R. U. Jänicke, and K. Schulze-Osthoff. 2003. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ. 10:76-100.
65. Maki, A., M. Matsuda, M. Asakawa, H. Kono, H. Fujii, and Y. Matsumoto. 2004. Decreased expression of CD28 coincides with the down-modulation of CD3zeta and augmentation of caspase-3 activity in T cells from hepatocellular carcinoma-bearing patients and hepatitis C virus-infected patients. J. Gastroenterol. Hep-atol. 19:1348-1356.
66. Chowdhury, I., B. Tharakan, and G. K. Bhat. 2008. Caspases - an update. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 151:10-27.
67. Wilhelm, S., H. Wagner, and G. Häcker. 1998. Activation of caspase-3-like enzymes in non-apoptotic T cells. Eur. J. Immunol. 28:891-900.
68. Alam, A., L. Y. Cohen, S. Aouad, and R. P. Sékaly. 1999. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J. Exp. Med. 190:1879-1890.
69. Kennedy, N. J., T. Kataoka, J. Tschopp, and R. C. Budd. 1999. Caspase activation is required for T cell proliferation. J. Exp. Med. 190:1891-1896.
70. Conejo-Garcia, J. R., F. Benencia, M. C. Courreges, P. A. Gimotty, E. Khang, R. J. Buckanovich, K. A. Frauwirth, L. Zhang, D. Katsaros, C. B. Thompson, et al. 2004. Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28-antitumor T cells. Cancer Res. 64:2175-2182.
71. Sutherland, C. L., N. J. Chalupny, K. Schooley, T. VandenBos, M. Kubin, and D. Cosman. 2002. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J. Immunol. 168:671-679.
72. Li, C., B. Ge, M. Nicotra, J. N. Stern, H. D. Kopcow, X. Chen, and J. L. Strominger. 2008. JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity. Proc. Natl. Acad. Sci. USA 105:3017-3022.
73. Zapata, J. M., R. Takahashi, G. S. Salvesen, and J. C. Reed. 1998. Granzyme release and caspase activation in activated human T-lymphocytes. J. Biol. Chem. 273:6916-6920.
74. Harvey, N. L., J. A. Trapani, T. Fernandes-Alnemri, G. Litwack, E. S. Alnemri, and S. Kumar. 1996. Processing of the Nedd2 precursor by ICE-like proteases and granzyme B. Genes Cells 1:673-685.
75. Los, M., C. Stroh, R. U. Jänicke, I. H. Engels, and K. Schulze-Osthoff. 2001. Caspases: more than just killers? Trends Immunol. 22:31-34.
76. Olaussen, R. W., M. R. Karlsson, K. E. Lundin, J. Jahnsen, P. Brandtzaeg, and I. N. Farstad. 2007. Reduced chemokine receptor 9 on intraepithelial lymphocytes in celiac disease suggests persistent epithelial activation. Gastroenterology 132:2371-2382.
77. Tomasello, E., P. O. Desmoulins, K. Chemin, S. Guia, H. Cremer, J. Ortaldo, P. Love, D. Kaiserlian, and E. Vivier. 2000. Combined natural killer cell and dendritic cell functional deficiency in KARAP/DAP12 loss-of-function mutant mice. Immunity 13:355-364.
78. Wee, L. J., T. W. Tan, and S. Ranganathan. 2007. CASVM: web server for SVM-based prediction of caspase substrates cleavage sites. Bioinformatics 23:3241-3243.